|
 |
|
|
|
|
Tripep: The ChronVac-C(R) Study Has Been Successfully Completed With Good Safety And Favorable Clinical Data (Medical News Today)
Mon Nov 30 03:40:36 PST 2009
All samples from the 12 patients with chronic Hepatitis C genotype 1 treated with Tripep's therapeutic vaccine ChronVac-C® have now been collected. The treatment was found to be safe, immunogenic and had transient effects on the serum levels of hepatitis C virus. This provides a proof-of-concept...
Read full article »
|
|
Tripep completes clinical trial of ChronVac-C for Hepatitis C virus treatment (News-Medical-Net)
Fri Nov 27 03:09:33 PST 2009
All samples from the 12 patients with chronic Hepatitis C genotype 1 treated with Tripep’s therapeutic vaccine ChronVac-C have now been collected. The treatment was found to be safe, immunogenic and had transient effects on the serum levels of hepatitis C virus.
Read full article »
|
|
Human Genome Sciences submits Zalbin BLA to US FDA to treat chronic hepatitis C (PharmaBiz)
Thu Nov 26 23:51:25 PST 2009
Human Genome Sciences, Inc has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Zalbin (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal phase-3 clinical trials showing that...
Read full article »
|
|
Antiviral Therapy To Treat Hepatitis C Is Declining In The US, An Alarming Trend (Medical News Today)
Thu Nov 26 04:35:35 PST 2009
Researchers from the University of Michigan determined that only 663,000 of the approximately 3.9 million Americans with hepatitis C virus (HCV) infection received antiviral therapy between 2002 and 2007. Treatment rates appear to be declining, in part because only half of the patients know they...
Read full article »
|
|
BioWatch: HGS seeks OK for hepatitis C treatment (Gazette.net)
Thu Nov 26 02:37:54 PST 2009
As expected, Human Genome Sciences has applied for federal regulatory approval to market its new treatment for hepatitis C.
Read full article »
|
|
Alarming Trend -- Antiviral Therapy To Treat Hepatitis C Is Declining In The US (redOrbit)
Tue Nov 24 16:09:00 PST 2009
Research suggests lack of diagnosis is primary barrier to treatmentResearchers from the University of Michigan determined that only 663,000 of the approximately 3.9 million Americans with hepatitis C virus (HCV) infection received antiviral therapy between 2002 and 2007.
Read full article »
|
|
Pharmasset: hepatitis C drug trial will continue (AP via Yahoo! News)
Mon Nov 23 10:56:21 PST 2009
Pharmasset Inc. said Monday that it will continue enrolling patients in a clinical trial of RG7128, a drug that is designed to treat the liver disease hepatitis C.
Read full article »
|
|
Alarming trend: Antiviral therapy to treat hepatitis C is declining in the US (Science Daily)
Tue Nov 24 06:21:23 PST 2009
Researchers have determined that only 663,000 of the approximately 3.9 million Americans with hepatitis C virus (HCV) infection received antiviral therapy between 2002 and 2007. If this disturbing trend continues, by 2030 less than 15 percent of liver-related deaths from HCV will be prevented by...
Read full article »
|
|
Human Genome Sciences Submits Biologics License Application To FDA For ZALBIN™ (Medical News Today)
Sun Nov 29 03:40:16 PST 2009
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
Read full article »
|
|
Alarming trend -- antiviral therapy to treat hepatitis C is declining in the US (PhysOrg)
Tue Nov 24 03:52:14 PST 2009
Researchers from the University of Michigan determined that only 663,000 of the approximately 3.9 million Americans with hepatitis C virus (HCV) infection received antiviral therapy between 2002 and 2007. Treatment rates appear to be declining, in part because only half of the patients know they...
Read full article »
|
